GlassScriptPhysician profile
Sohrab Singh
NPI 1992496111
$2,295.71
in general payments reported to CMS, 2019-2025
13 companies · $649 in 2025
The $649 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.85 · 2023: $1,014 · 2024: $611 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.87 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $808.46 | 2023-2025 | Linq II, Azure Xt Dr Mri Surescan, Symplicity G3 |
| Astrazeneca Pharmaceuticals LP | $453.56 | 2022-2024 | Farxiga |
| Shockwave Medical, INC | $387.20 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $255.67 | 2025 | Mitraclip, Triclip |
| Merck Sharp & Dohme LLC | $74.62 | 2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $73.76 | 2023-2024 | Camzyos |
| Harmony Biosciences LLC | $54.99 | 2024 | |
| Pfizer INC. | $39.64 | 2023-2024 | |
| Amgen INC. | $38.99 | 2025 | Repatha |
| Novo Nordisk INC | $34.13 | 2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $34.00 | 2023 | |
| Cordis US Corp. | $25.11 | 2025 | Mynx Control Venous |
| Chiesi USA, INC. | $15.58 | 2023 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohrab Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.